Search Results - "Ochoa de Olza, M"

Early-drug development in the era of immuno-oncology: are we ready to face the challenges? by Ochoa de Olza, M., Oliva, M., Hierro, C., Matos, I., Martin-Liberal, J., Garralda, E.

“…The classical development of drugs has progressively faded away, and we are currently in an era of seamless drug-development, where first-in-human trials…”
Get full text

Early interventions to detect potential drug–drug interactions on patient eligibility for phase 1 clinical trials by Azaro, A, Ghiglione, L, Valdivia, C, Munné, M, Renedo, B, Sabaté, N, Alcalde, M, Braña, I, Hierro, C, Martin-Liberal, J, Ochoa de Olza, M, Argiles Martínez, G, Vilaró, M, Tabernero, J, Rodon, J

“…An abstract of a study by Azaro et al determining the potential drug-drug interactions (DDI) on patient eligibility for phase 1 clinical trials is presented…”
Get full text

The utility of ancillary tests in monitoring cutaneous melanoma patients to detect visceral metastasis by Ferreres, J.R., Marcoval, J., Fodge, K., de Olza, M. Ochoa, Viñals, A., Fabra, A.

Get full text

Early-drug development in the era of immuno-oncology: are we ready to face the challenges? by Ochoa de Olza, M.O., Oliva, M., Hierro, C., Matos, I., Martin-Liberal, J., Garralda, E.

Get full text

Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer by Lin, C.-C., Taylor, M., Boni, V., Brunsvig, P.F., Geater, S.L., Salvagni, S., Garrido Lopez, P., Özgüroğlu, M., Sriuranpong, V., Ponce Aix, S., Ascierto, P.A., Fasolo, A., Sezer, A., Kowalski, D.M., Faris, J.E., Cameron, S., Mataraza, J., Wu, H., Antona, V., Ochoa de Olza, M.

Get full text

Refining criteria of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) to improve clinical applicability by Matos Garcia, I., García Ruiz, A., Martin-Liberal, J., Hierro, C., Ochoa De Olza Amat, M., Viaplana, C., Mur, G., Vieito Villar, M., Brana, I., Azaro, A., Perez, C., Rodriguez Freixinos, V., Argiles, G., Oliveira, M., Felip Font, E., Muñoz-Couselo, E., Tabernero, J., Dienstmann, R., Garralda, E.

Get full text

Immune prognostic index (IPI) and hyper-progressive disease (HPD) in patients (pts) exposed to targeted agents (TAs) in phase I trials (Ph1T): Can lessons from immune checkpoint inhibitors (ICIs) be translated to other scenarios? by Matos Garcia, I., Azaro, A., Viaplana, C., Hierro, C., Martin-Liberal, J., Brana, I., Gardeazabal, I., Gomila, P., Vieito Villar, M., Ochoa De Olza Amat, M., Elez Fernandez, E., Oliveira, M., Oaknin, A., Verdaguer, H., Navarro Mendivil, A., Alsina, M., Tabernero, J., Macarulla Mercade, T., Dienstmann, R., Garralda, E.

Get full text

Tumor infiltrating lymphocytes (TILs) and PDL1 expression as prescreening enrichment biomarkers of clinical benefit to immune checkpoint inhibitors (CI) in early clinical trials (ECT) by Martin-Liberal, J., Pagliuca, F., Hierro, C., Viaplana, C., Muñoz Couselo, E., Capdevila, J., Matos, I., Fariñas Madrid, L., Zamora, E., Braña Garcia, I., Elez Fernandez, E., Ochoa De Olza Amat, M., Azaro, A., Alsina, M., Vieito Villar, M., Fasani, R., Tabernero, J., Garralda, E., Dienstmann, R., Nuciforo, P.G.

Get full text

Vall d’Hebron Institute of Oncology (VHIO) immuno-oncology prognostic index (VIO): A new tool for improved patient (pt) selection in phase I (Ph1) trials with immune checkpoint inhibitors (ICI) by Hierro, C., Matos, I., Martin-Liberal, J., Ochoa De Olza Amat, M., Felip, E., Costa Rivas, M., Vieito Villar, M., Brana, I., Azaro, A., Perez-Gago, M.C., Gros, A., Carles, J., Oaknin, A., Macarulla, T., Saura, C., pardo, N., Muñoz-Couselo, E., Tabernero, J., Dienstmann, R., Garralda, E.

Get full text

Patterns of Visceral Metastasis in Cutaneous Melanoma: A Descriptive Study by Marcoval, J, Ferreres, J.R, Martín, C, Gómez, S, Penín, R.M, Ochoa de Olza, M, Fabra, À

“…Abstract Background and objectives Some types of cancer tend to spread to certain organs. In the case of melanoma, uveal melanoma spreads almost exclusively to…”
Get full text

429 (PB417): Lessons learned from a pan-cancer exploratory Liquid Biopsy (LB) profiling: the PREICO-LB project by Hierro, C., Notario, L., Bergamino, M., Sabat, P., Soto-Castillo, J.J., Calvo, M., Oliva, M., Jove, M., Ruffinelli, J.C., Mosteiro, M.A., de Olza, M. Ochoa, Carcereny, E., Balaña, D., Gonzalez, M.I., Fina, C., Gil-Martin, M., Nadal, E., Azuara, D., Lazaro, C., Martin-Liberal, J.

Get full text

P272 A nomogram for predicting survival in Muscle-Invasive Bladder Cancer (MIBC) patients (p) treated with Neoadjuvant Chemotherapy (NAC) by Pérez-Criado, I., Chekhun, S., Figols, M., González, A., Etxaniz, O., Fernández, C., Rivas, C., Bautista, A., Gago, J.L., Bernal, S., Ulises, F., Ochoa De Olza, M., Delany, B., Hernandez, A., Quispe, M., Domenech, M., Esteve, A., Font, A.

Get full text

1277PImmune checkpoint inhibitors (ICIs) as “chemotherapy (Ctx) sensitization” strategy in advanced solid tumours by Montana, F J Ros, Matos, I, Vilacampa, G, Azaro, A, Martin-Liberal, J, Hierro, C, Brana, I, Viaplana, C, Villar, M Vieito, Gardeazabal, I, Saura, C, Madrid, L Fariñas, Mercade, T Macarulla, Saavedra, O, Pardo, N, de Olza, M Ochoa, Muñoz-Couselo, E, Tabernero, J, Dienstmann, R, Garralda, E

“…Abstract Background The anti-tumor activity of Ctx after ICIs has been poorly investigated in patients with refractory advanced solid tumors. A recent…”
Get full text

1277P - Immune checkpoint inhibitors (ICIs) as “chemotherapy (Ctx) sensitization” strategy in advanced solid tumours by Montana, F J Ros, Matos, I., Vilacampa, G., Azaro, A., Martin-Liberal, J., Hierro, C., Brana, I., Viaplana, C., Villar, M Vieito, Gardeazabal, I., Saura, C., Madrid, L Fariñas, Mercade, T Macarulla, Saavedra, O., Pardo, N., de Olza, M Ochoa, Muñoz-Couselo, E., Tabernero, J., Dienstmann, R., Garralda, E.

“…The anti-tumor activity of Ctx after ICIs has been poorly investigated in patients with refractory advanced solid tumors. A recent communication suggested that…”
Get full text

Immune checkpoint inhibitors (ICIs) as “chemotherapy (Ctx) sensitization” strategy in advanced solid tumours by Montana, F J Ros, Matos, I., Vilacampa, G., Azaro, A., Martin-Liberal, J., Hierro, C., Brana, I., Viaplana, C., Villar, M Vieito, Gardeazabal, I., Saura, C., Madrid, L Fariñas, Mercade, T Macarulla, Saavedra, O., Pardo, N., de Olza, M Ochoa, Muñoz-Couselo, E., Tabernero, J., Dienstmann, R., Garralda, E.

Get full text

Outcomes of malignant pleural mesothelioma (MPM) patients (p) treated with immune-oncology drugs (IO) in clinical trials by Cedres, S., Martinez Marti, A., Navarro, A., Pardo, N., Remon, J., Matos, I., Ochoa de Olza, M., Hierro, C., Martin Liberal, J., Miquel, J.M., Viaplana, C., Villacampa Javierre, G., Dienstmann, R., Felip Font, E.

Get full text

1159PPhase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer by Lin, C-C, Taylor, M, Boni, V, Brunsvig, P F, Geater, S L, Salvagni, S, Garrido Lopez, P, Özgüroğlu, M, Sriuranpong, V, Ponce Aix, S, Ascierto, P A, Fasolo, A, Sezer, A, Kowalski, D M, Faris, J E, Cameron, S, Mataraza, J, Wu, H, Antona, V, Ochoa de Olza, M

Get full text

Early-drug development in the era of immuno-oncology: are we ready to face the challenges? by Ochoa de Olza, M O, Oliva, M, Hierro, C, Matos, I, Martin-Liberal, J, Garralda, E

Get full text

Mutational load by targeted next generation sequencing (NGS) panels as potential biomarker of response to checkpoint inhibitors by Martin-Liberal, J., de Olza, M. Ochoa, Hierro, C., Cruz, C., Rodriguez, C., Brana, I., Vivancos, A., Dienstmann, R., Rodon, J., Tabernero, J.

Get full text

108 - Early interventions to detect potential drug–drug interactions on patient eligibility for phase 1 clinical trials by Azaro, A., Ghiglione, L., Valdivia, C., Munné, M., Renedo, B., Sabaté, N., Alcalde, M., Braña, I., Hierro, C., Martin-Liberal, J., Ochoa de Olza, M., Argiles Martínez, G., Vilaró, M., Tabernero, J., Rodon, J.

Get full text